364 related articles for article (PubMed ID: 24077405)
1. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Phan GQ; Rosenberg SA
Cancer Control; 2013 Oct; 20(4):289-97. PubMed ID: 24077405
[TBL] [Abstract][Full Text] [Related]
2. Adoptive Cell Therapy for Metastatic Melanoma.
Merhavi-Shoham E; Itzhaki O; Markel G; Schachter J; Besser MJ
Cancer J; 2017; 23(1):48-53. PubMed ID: 28114254
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
4. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
5. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
6. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
7. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
8. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
Svane IM; Verdegaal EM
Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
[TBL] [Abstract][Full Text] [Related]
9. Is antigen specificity the key to efficient adoptive T-cell therapy?
Labarriere N; Khammari A; Lang F; Dreno B
Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor.
Roncati L; Palmieri B
Int J Dermatol; 2020 Jul; 59(7):763-769. PubMed ID: 32441324
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
15. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
Martins F; Orcurto A; Michielin O; Coukos G
Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
[TBL] [Abstract][Full Text] [Related]
17. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Rosenberg SA; Yang JC; Sherry RM; Kammula US; Hughes MS; Phan GQ; Citrin DE; Restifo NP; Robbins PF; Wunderlich JR; Morton KE; Laurencot CM; Steinberg SM; White DE; Dudley ME
Clin Cancer Res; 2011 Jul; 17(13):4550-7. PubMed ID: 21498393
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G
Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
[TBL] [Abstract][Full Text] [Related]
20. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Burns WR; Zhao Y; Frankel TL; Hinrichs CS; Zheng Z; Xu H; Feldman SA; Ferrone S; Rosenberg SA; Morgan RA
Cancer Res; 2010 Apr; 70(8):3027-33. PubMed ID: 20395199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
